Breakout Stocks Alert Under $1: TCBP, NVVE, TCON, CEI, NRBO

The stock market offers a number of options to investors who are willing to research and look for opportunities across a broad classification of stocks. For instance, some opportunities may also be in stocks that trade under a dollar. Here is a look into five stocks trading under $1 which could well be worth tracking at this point in time.

TC BioPharma PLC (NASDAQ:TCBP) – The clinical-stage biotech firm is involved in the development of platform allogenic gamma-delta T cell therapies to treat cancer. On July 31, TC BioPharma PLC announced that it had been successful in regaining compliance with the Nasdaq Stock Market Listing Rule 5550(b). The company’s American depository shares would continue to be listed on NASDAQ, as a consequence. It had been reported on January 19 that the company had received a letter from the listing qualification staff of NASDAQ.

In the letter, it was noted that the company had failed to regain compliance with the minimum Market Value of Listed Securities rule of $35,000,000, the minimum for continued listing on the exchange. The company submitted a plan to regain compliance later on and on July 27, 2023, it was apprised to the company by NASDAQ that it had regained compliance.

Nuvve Holding Corp (NASDAQ:NVVE) – The company, which is a worldwide leader in the field of vehicle-on-grid technology and deployments, made a key announcement on July 13. Nuvve Holding Corp announced that it would supply NRT Bus with 25 bi-directional Nuvve DC Rapid HD Charging Stations.

The charging stations are for Lawrence Public Schools located in Lawrence, Massachusetts. The chargers would be able to power a fleet of 25 new electric school buses made by Thomas Built Buses. The buses had been acquired under the auspices of the Clean School Bus Grant awarded by the EPA in Massachusetts in 2022.

TRACON Pharmaceuticals Inc (NASDAQ: TCON) – The clinical stages biopharmaceutical company is known for deploying a cost-efficient and CRO-independent product development platform for taking forwards its pipeline of unique cancer therapeutics. The platform also enables the company to get into partnerships with other life science companies.

The company believes that its platform could be used by other companies in the United States which may not have the commercial or clinical capabilities to be CRP independent. Yesterday, TRACON Pharmaceuticals Inc was in the news after it announced that it was going to announce its financial and operating results for the second fiscal quarter of 2023 following the closure of markets on August 14, 2023.

The company also revealed that it would hold a conference call on the same day for the purpose of providing updates on its corporate activities and discussing the financial results further. The conference call would also be made available in a webcast and would also be available on the TRACON Pharmaceuticals website for 60 days. 

Camber Energy Inc (NASDAQ: CEI) – On August 1 Camber Energy Inc was in the news cycle after it announced that it has completed the acquisition of Viking Energy Group Inc. The company completed the acquisition of all the issued and outstanding shares of Viking Energy that it already did not own. Viking also became a fully owned subsidiary unit of Camber Energy effective August 1 and its shares stopped trading on the OTCQB. Camber remained the sole publicly traded company among the two. The acquisition brought the long-standing customized energy and power solutions of Viking Energy under Camber’s fold.

Additionally, the company also got hold of a number of ready-for-market portfolios of a range of technologies in the carbon capture, clean energy, utility, and waste treatment spaces. However, one of the more important fallouts from the transaction could be the fact that Camber would also inherit a team of seasoned professionals, significant growth opportunities, and major industry relationships.

NeuroBo Pharmaceuticals Inc (NASDAQ: NRBO) – The clinical-stage biotech firm is working on ways to bring about changes to the treatment of cardiometabolic diseases. On August 2 the company announced that it had signed a term sheet with MThera Pharma Co Ltd. The term sheet laid out the terms under which NeuroBo Pharmaceuticals Inc would out-license the worldwide rights outside of South Korea. As per the provisions of the term sheet, MTHERA would be allowed to conduct fresh research for acquiring new patents for NB 01 and also conduct clinical trials.

It would also include the possibility of Phase 3 clinical trial to be conducted in the United States for the commercialization of NB 01 in the future. However, the financial conditions of the term sheet had not been disclosed. The Chief Executive Officer and Interim President of the company Joseph Hooker spoke about the situation too. He noted that MTHERA held considerable experience in quality control, clinical development, and manufacturing of natural medicines. That made MTHERA the perfect partner for NeuroBo Pharmaceuticals.